NT5E and neoplasm: In an effort to overcome purinergic immunometabolic suppression and improve NK cell-mediated anti-tumor function, we have developed an immunotherapeutic treatment approach which combines non-virally engineered NKG2D-retargeted CAR-NK-92 (NKG2D.CAR-NK-92) cells alongside neutralization of CD73 ectonucleotidase activity (Figure 1B).